Loss of epithelial membrane protein-2 expression confers an independent prognosticator in nasopharyngeal carcinoma: A cohort study

Yi Hsien Chen, Li Ching Wu, Wen Ren Wu, Hung Jung Lin, Sung Wei Lee, Ching Yih Lin, Shih Lun Chang, Nan Haw Chow, Hsuan Ying Huang, Chien Feng Li, Han Ping Hsu, Yow Ling Shiue

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To evaluate the expression of epithelial membrane protein-2 (EMP2) protein and its clinicopathological associations in patients with nasopharyngeal carcinoma. Design: Retrospective population-based cohort study. Setting: This study was based on a biobank in Chi-Mei Medical Center (Tainan, Taiwan) from 1993 to 2002. Participants: Biopsies of 124 consecutive nasopharyngeal carcinoma patients without initial distant metastasis and treated with consistent guidelines were assessed. Immunoexpressions of EMP2 were analysed and the outcomes were correlated with clinicopathological features and patient survivals. Primary and secondary outcome measures: Immunoexpressions of EMP2 were analyzed and the outcomes were correlated with clinicopathological features and patient survivals. Results: Loss of EMP2 expression (49.2%) was correlated with advanced primary tumour (p=0.044), nodal status (p=0.045) and the 7th American Joint Committee on Cancer stage (p=0.027). In multivariate analyses, loss of EMP2 expression emerged as an independent prognosticator for worse disease-specific survival (DSS; p=0.015) and local recurrence-free survival (LRFS; p=0.030), along with the American Joint Committee on Cancer stages IIIeIV (p=0.034, DSS; p=0.023, LRFS). Conclusions: Loss of EMP2 expression is common and associated with adverse prognosticators and might confer tumour aggressiveness through hampering its interaction with specific membrane protein(s) and hence the downstream signal transduction pathway(s).

Original languageEnglish
Article numbere000900
JournalBMJ open
Volume2
Issue number2
DOIs
Publication statusPublished - 2012 May 17

Fingerprint

Membrane Proteins
Cohort Studies
Survival
Neoplasms
Nasopharyngeal carcinoma
Taiwan
Signal Transduction
Multivariate Analysis
Outcome Assessment (Health Care)
Guidelines
Neoplasm Metastasis
Biopsy
Recurrence
Population
Proteins

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Chen, Yi Hsien ; Wu, Li Ching ; Wu, Wen Ren ; Lin, Hung Jung ; Lee, Sung Wei ; Lin, Ching Yih ; Chang, Shih Lun ; Chow, Nan Haw ; Huang, Hsuan Ying ; Li, Chien Feng ; Hsu, Han Ping ; Shiue, Yow Ling. / Loss of epithelial membrane protein-2 expression confers an independent prognosticator in nasopharyngeal carcinoma : A cohort study. In: BMJ open. 2012 ; Vol. 2, No. 2.
@article{0ca4ad5f6c3149f689a5cf1bdb3394dc,
title = "Loss of epithelial membrane protein-2 expression confers an independent prognosticator in nasopharyngeal carcinoma: A cohort study",
abstract = "Objective: To evaluate the expression of epithelial membrane protein-2 (EMP2) protein and its clinicopathological associations in patients with nasopharyngeal carcinoma. Design: Retrospective population-based cohort study. Setting: This study was based on a biobank in Chi-Mei Medical Center (Tainan, Taiwan) from 1993 to 2002. Participants: Biopsies of 124 consecutive nasopharyngeal carcinoma patients without initial distant metastasis and treated with consistent guidelines were assessed. Immunoexpressions of EMP2 were analysed and the outcomes were correlated with clinicopathological features and patient survivals. Primary and secondary outcome measures: Immunoexpressions of EMP2 were analyzed and the outcomes were correlated with clinicopathological features and patient survivals. Results: Loss of EMP2 expression (49.2{\%}) was correlated with advanced primary tumour (p=0.044), nodal status (p=0.045) and the 7th American Joint Committee on Cancer stage (p=0.027). In multivariate analyses, loss of EMP2 expression emerged as an independent prognosticator for worse disease-specific survival (DSS; p=0.015) and local recurrence-free survival (LRFS; p=0.030), along with the American Joint Committee on Cancer stages IIIeIV (p=0.034, DSS; p=0.023, LRFS). Conclusions: Loss of EMP2 expression is common and associated with adverse prognosticators and might confer tumour aggressiveness through hampering its interaction with specific membrane protein(s) and hence the downstream signal transduction pathway(s).",
author = "Chen, {Yi Hsien} and Wu, {Li Ching} and Wu, {Wen Ren} and Lin, {Hung Jung} and Lee, {Sung Wei} and Lin, {Ching Yih} and Chang, {Shih Lun} and Chow, {Nan Haw} and Huang, {Hsuan Ying} and Li, {Chien Feng} and Hsu, {Han Ping} and Shiue, {Yow Ling}",
year = "2012",
month = "5",
day = "17",
doi = "10.1136/bmjopen-2012-000900",
language = "English",
volume = "2",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "2",

}

Chen, YH, Wu, LC, Wu, WR, Lin, HJ, Lee, SW, Lin, CY, Chang, SL, Chow, NH, Huang, HY, Li, CF, Hsu, HP & Shiue, YL 2012, 'Loss of epithelial membrane protein-2 expression confers an independent prognosticator in nasopharyngeal carcinoma: A cohort study', BMJ open, vol. 2, no. 2, e000900. https://doi.org/10.1136/bmjopen-2012-000900

Loss of epithelial membrane protein-2 expression confers an independent prognosticator in nasopharyngeal carcinoma : A cohort study. / Chen, Yi Hsien; Wu, Li Ching; Wu, Wen Ren; Lin, Hung Jung; Lee, Sung Wei; Lin, Ching Yih; Chang, Shih Lun; Chow, Nan Haw; Huang, Hsuan Ying; Li, Chien Feng; Hsu, Han Ping; Shiue, Yow Ling.

In: BMJ open, Vol. 2, No. 2, e000900, 17.05.2012.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Loss of epithelial membrane protein-2 expression confers an independent prognosticator in nasopharyngeal carcinoma

T2 - A cohort study

AU - Chen, Yi Hsien

AU - Wu, Li Ching

AU - Wu, Wen Ren

AU - Lin, Hung Jung

AU - Lee, Sung Wei

AU - Lin, Ching Yih

AU - Chang, Shih Lun

AU - Chow, Nan Haw

AU - Huang, Hsuan Ying

AU - Li, Chien Feng

AU - Hsu, Han Ping

AU - Shiue, Yow Ling

PY - 2012/5/17

Y1 - 2012/5/17

N2 - Objective: To evaluate the expression of epithelial membrane protein-2 (EMP2) protein and its clinicopathological associations in patients with nasopharyngeal carcinoma. Design: Retrospective population-based cohort study. Setting: This study was based on a biobank in Chi-Mei Medical Center (Tainan, Taiwan) from 1993 to 2002. Participants: Biopsies of 124 consecutive nasopharyngeal carcinoma patients without initial distant metastasis and treated with consistent guidelines were assessed. Immunoexpressions of EMP2 were analysed and the outcomes were correlated with clinicopathological features and patient survivals. Primary and secondary outcome measures: Immunoexpressions of EMP2 were analyzed and the outcomes were correlated with clinicopathological features and patient survivals. Results: Loss of EMP2 expression (49.2%) was correlated with advanced primary tumour (p=0.044), nodal status (p=0.045) and the 7th American Joint Committee on Cancer stage (p=0.027). In multivariate analyses, loss of EMP2 expression emerged as an independent prognosticator for worse disease-specific survival (DSS; p=0.015) and local recurrence-free survival (LRFS; p=0.030), along with the American Joint Committee on Cancer stages IIIeIV (p=0.034, DSS; p=0.023, LRFS). Conclusions: Loss of EMP2 expression is common and associated with adverse prognosticators and might confer tumour aggressiveness through hampering its interaction with specific membrane protein(s) and hence the downstream signal transduction pathway(s).

AB - Objective: To evaluate the expression of epithelial membrane protein-2 (EMP2) protein and its clinicopathological associations in patients with nasopharyngeal carcinoma. Design: Retrospective population-based cohort study. Setting: This study was based on a biobank in Chi-Mei Medical Center (Tainan, Taiwan) from 1993 to 2002. Participants: Biopsies of 124 consecutive nasopharyngeal carcinoma patients without initial distant metastasis and treated with consistent guidelines were assessed. Immunoexpressions of EMP2 were analysed and the outcomes were correlated with clinicopathological features and patient survivals. Primary and secondary outcome measures: Immunoexpressions of EMP2 were analyzed and the outcomes were correlated with clinicopathological features and patient survivals. Results: Loss of EMP2 expression (49.2%) was correlated with advanced primary tumour (p=0.044), nodal status (p=0.045) and the 7th American Joint Committee on Cancer stage (p=0.027). In multivariate analyses, loss of EMP2 expression emerged as an independent prognosticator for worse disease-specific survival (DSS; p=0.015) and local recurrence-free survival (LRFS; p=0.030), along with the American Joint Committee on Cancer stages IIIeIV (p=0.034, DSS; p=0.023, LRFS). Conclusions: Loss of EMP2 expression is common and associated with adverse prognosticators and might confer tumour aggressiveness through hampering its interaction with specific membrane protein(s) and hence the downstream signal transduction pathway(s).

UR - http://www.scopus.com/inward/record.url?scp=84860904596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860904596&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2012-000900

DO - 10.1136/bmjopen-2012-000900

M3 - Article

C2 - 22492389

AN - SCOPUS:84860904596

VL - 2

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 2

M1 - e000900

ER -